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INTRODUCTION 
BACKGROUND AND OBJECTIVES 
The 2012 ES/EACTS Guidelines on the Management of Valvular Heart Disease recommend surgical 
aortic valve replacement to severe aortic stenosis (AS) patients who: 1) display any symptoms related to 
AS; 2) will undergo coronary artery bypass graft or surgery of the aorta or another valve; 3) are 
asymptomatic but present with systolic LV dysfunction (Left Ventricle Ejection Faction (LVEF)<50%) 
not attributable to any other cause and 4) are asymptomatic but display abnormal exercise test showing 
symptoms on exercise clearly related to AS1. However, recent studies have shown that a more proactive 
treatment strategy promoting surgery before the onset of symptoms may bring greater benefit2. The 
objective of this paper is to review currently existing literature in order to investigate the relationship 
between left ventricular remodeling, prognosis and therapeutic outcomes in AS, and to determine the 
potential thereof in recommending more proactive surgical approaches to asymptomatic patients. The 
bibliographic research conducted is summarized in figure 1. 
DEFINITION OF AORTIC STENOSIS AND ITS SEVERITY 
Aortic stenosis is a pathologic narrowing of the aortic valve characterized by a restricted outflow from the 
left ventricle into the aorta. AS is both a common and serious cardiovascular pathology3 as it causes a 
significant increase in both mortality and morbidity of affected individuals4. The restriction of left 
ventricular outflow increases afterload and interferes with left ventricular function, promoting a series of 
changes in the heart, including left ventricular remodelling5. Being a common pathology whose incidence 
increases with age, it stands to reason that the disease burden it provokes in the developed world will 
increase over time, given population ageing3,6, which reinforces the need to better understand the 
pathophysiology of AS. 
A multifactorial etiology, with a complex interaction of anatomical, clinical and genetic factors, 
contributes to the genesis of AS.7 AS’ initial pathophysiology resembles that of atherosclerosis, with a 
significant overlap of risk factors for both diseases8,9, followed by a calcification and propagation stage, 
where a complex process of fibrosis occurs, culminating with the calcification and narrowing of the valve 
and obstruction of left ventricular outflow.10 
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Roberts et al studied the natural history of 260 AS patients not subjected to surgical treatment over 50 
years. This author reported that heart failure, angina pectoris or syncope, were overwhelmingly common 
(68% of men and 67% of women); that the onset of any cardiac symptomatology was associated with an 
exceptionally dire prognosis, supporting a median survival of 20 months after symptom onset; and that 
patients with cardiac symptomatology were at higher risk for death from cardiac events (both sudden and 
non-sudden) when compared to the asymptomatic group (OR: 3.61).11 
The therapeutic gold standard for AS is aortic valve replacement (AVR), as confirmed by numerous 
studies demonstrating dramatic symptomatic relief and improvement of long-term survival12. An 
alternative to surgical replacement is transcatheter aortic valve implantation (TAVI), especially for 
patients with high surgical risk who cannot undergo surgical aortic valve replacement (SAVR)13. As far 
as medical therapy is concerned, no therapeutic regimen has been able to convincingly delay the 
progression of AS or reduce mortality once symptoms are established, and thus, it is limited to patients 
who require pre-surgical stabilization or for symptomatic management in patients who cannot  or who 
choose not to undergo SAVR or TAVI.14–16 
The 2012 ES/EACTS Guidelines on the Management of Valvular Heart Disease defined severe AS as 
having a valve area under 1 cm2; an indexed valve area under 0.6 cm²/m²; a mean gradient greater than 
40mmHg; a maximum jet velocity over 4.0 m/s; and a velocity ratio under 0.251. The American Heart 
Association Guidelines for the Management of Patients with Valvular Heart Disease17 define four main 
stages of AS, summarized in Table 1. Mild LV dysfunction can be observed as early as stage B and LV 
remodeling as early as stage C. The distinction between these stages is made primarily through the 
presence of symptomatology, the aortic valve morphology and area, the pressure gradient between the LV 
and the aorta, and the LVEF.18,19 These latter 3 parameters are determined through echocardiographic 
studies, which are the cornerstone of AS staging18,19, although other imaging procedures may also have a 
diagnostic role.20,21 
It is important to distinguish between the various stages of the pathology, given the heavy implications 
upon prognosis and therapeutic decisions.22,23 The decision to submit the patient to surgical treatment is 
based on a risk-benefit assessment of surgical risk associated with the procedure weighed against the risk 
posed by the lack of surgical correction. The current ES/EACTS guidelines1 and AHA guidelines 
recommend against routine aortic valve replacement for asymptomatic patients on the basis that these 
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patients possess a low risk of cardiac sudden death (>1%) when compared to age-matched controls17. The 
indications for AVR according to ES/EACTS guidelines are summarized in Table 2. 
LEFT VENTRICULAR REMODELLING IN THE CONTEXT OF AORTIC 
STENOSIS 
Ventricular remodeling comprises the functional and anatomic changes undergone by the heart in 
response to either physiological stimuli, like exercise24, high altitude25, pregnancy26 or to various 
pathological stimuli, like volume overload, as in valvular regurgitation,27 pressure overload, as in AS,28or 
other situations where a more complex forms of overload may be present, like acute myocardial infarction 
(AMI)27.  
Various classifications exist for LVR and LVH. Verma et al, in the VALIANT study, defined 3 types of 
LVR: concentric remodeling, concentric hypertrophy and eccentric hypertrophy.29 Khouri et al suggested 
an expansion of this system with subgroups for each category, namely indeterminate eccentric, dilated 
eccentric, thick concentric and thick and dilated concentric LVH.30 Situations of volume overload tend to 
produce eccentric hypertrophy26, whereas situations of pressure overload tend to produce concentric 
hypertrophy.28  
AS imposes a chronic high afterload to the left ventricle, triggering compensatory changes aimed at 
reducing wall stress and maintaining cardiac output. The LV undergoes an increase in both relative wall 
thickness (RWT) and LV Mass Index (LVMi), which is the LV Mass (LVM) adjusted to body surface 
area (BSA)29, in what is known as concentric hypertrophy. The increase in LVM negatively affects the 
contractility of heart31. However, the increase in afterload is not the only mechanism involved in LVH in 
the context of AS. Indeed, LVH is a complex, multifactorial process, modulated by variables such as 
gender32, neurohumoral activation18, and the association of AS with various comorbidities, like obesity 
and hypertension33. 
The aforementioned changes in LV wall thickness and geometry34 occur simultaneously to a fibrotic 
process where myocardial areas of apoptosis are replaced by fibrosis35, with the occurrence of a 
pathological sequence of progression from myocyte hypertrophy, to apoptosis, to fibrosis36, with 
correspondent fibroblast recruitment and increase in fibrotic content of the myocardium37. The 
predominant pattern of fibrosis occurring in the context of AS is midwall fibrosis and its presence is 
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usually established via Late Gadolinium Enhancement (LGE) in a cardiac MRI38. The exact trigger for 
apoptosis in these circumstances is unknown, but both direct mechanical factors, such as wall stretch, and 
angiotensin II appear to play a relevant role39–41. This increase in myocardial fibrotic content ultimately 
produces a worse prognosis, due either to worsening of diastolic function33 or to the increased 
arrythmogenic potential of the fibrotic heart42 and cardiac sudden death43,44. The increased cardiac wall 
stress promotes an increase in circulating natriuretic peptides, particularly N-terminal B-type natriuretic 
peptide (NtBNP), as it appears capable of predicting symptom free survival and post-operative 
outcomes45. Myocardial ischemia is also a relevant process in LVH. It occurs mostly as the 
microvasculature of the heart becomes unable to keep up with the growing metabolic demands of the left 
ventricular mass46, and thus, may also be a relevant contributor to the increasing fibrosis of the 
myocardium. Reflecting the influence of myocardial cell death in this process, higher circulating levels of 
cardiac troponins can be found, particularly with the usage of high sensitivity assays.47  
While these changes are initially adaptive, with chronicity they tend to become maladaptive48 and thus, 
LVH has a significant impact on the prognosis of AS, being an independent determinant of higher 
mortality and morbidity from cardiac events.27,49–51 
LEFT VENTRICULAR REVERSE REMODELLING AFTER AORTIC VALVE 
REPLACEMENT 
LV Reverse Remodeling (LVRR) is seen in AS patients who successfully undergo AVR, both with 
SAVR techniques or TAVI techniques52 , defined as a normalization of LVMi, RWT, and other 
measurements of hypertrophy as well as recovery of cardiac function53.  
However, LVRR is frequently incomplete. Gavina et al54studied the presence of residual LVH in a post-
SAVR setting, and observed that, in this cohort, 44% of patients maintained some degree of LVH after 
valve replacement, and that this incomplete regression heralded a worse prognosis, especially for women. 
Magalhães et al55 performed a similar analysis regarding extension of the LVRR process in a TAVI 
setting and reported partial or complete normalization of LVMi and RWT in 24% of the population at 1 
year follow-up post-TAVI, without a corresponding normalization of left atrial dimensions. In TRITON 
trial, Haverich et al56 reported a mean reduction of 14% in LVMi at 1 year follow-up, and a 16% 
reduction at 3 years after surgical treatment of AS with a Next Generation Surgical Aortic Valve. 
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Similarly to the extent of LVH, LVRR is modulated by various factors apart from successful AVR. 
Hypertension appears to play an exceedingly important role, as those AS patients without hypertension 
who undergo AVR have a much greater amount of LVRR when compared to those with hypertension 
independently of total afterload32.Prosthetic-patient mismatch57 is also independently associated with a 
negative impact on the extent of LVRR
58
, as demonstrated in a large cohort of AS patients by Del Rizzo et 
al
59
. Gender also has an impact, with women having a tendency towards more complete LVH regression 
when compared to men
60,61
. 
POSITIVE OUTCOMES ASSOCIATED WITH EARLIER SURGICAL 
INTERVENTION 
Growing evidence begins to suggest, however, that surgical treatment strategies may effectively provide 
greater benefit to asymptomatic patients than previously believed.  
In a prospective study conducted over 10 years, Kang et al studied patients with asymptomatic severe AS 
randomized between two treatment groups, one treated with early surgery, as defined as elective surgery 
performed before formal indication per the most recent available guidelines, and one treated with the 
conventional treatment strategy. The authors reported a cardiac and all-cause risk of death of 0% and 6% 
in the early surgical treatment group, and a 24% and 32% risk for the same variable in the conventional 
treatment group, over a median follow-up period of 1501 days. Authors concluded that the benefits of 
early surgery outweighed all the risks, and thus, that it was an option for the asymptomatic very severe 
AS patient. Also this group presented more LVH regression and better LV systolic function in post-op 
echocardiographic studies, indicating that early surgery is able to prevent irreversible myocardial damage 
and fibrosis, and therefore reduce the risk of cardiac sudden death. 62 
In 2015, Taniguchi et al analyzed data from a large multicenter registry to compare long term outcomes 
of patients with asymptomatic severe AS who were treated with AVR (SAVR or TAVI) at diagnosis and 
those managed with traditional conservative strategies. The authors reported dire outcomes in the group 
managed with the currently recommended conservative strategy when compared to those who underwent 
AVR, with a cumulative 5-year incidence of death by all causes of 26.4% vs. 15.4% (p=0.009); a 
cumulative 5-year incidence of cardiovascular and aortic valve related death of 18.6% vs. 9.9% (p=0.01); 
and a cumulative 5-year incidence of sudden death of  5.8% vs. 3.6 % (p=0.06) thus concluding that the 
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dismal outcomes associated with conservative treatment strategies for severe asymptomatic AS patients 
are largely surpassed by earlier AVR2  
The AVATAR prospective, multicenter, randomized, controlled, parallel group, event-driven trial began 
in 2016 and aimed to evaluate the safety and efficacy of elective AVR for asymptomatic AS patients with 
preserved LVEF. To achieve this goal, a cohort of 312 asymptomatic patients with isolated AS and 
preserved LVEF will be randomized to one of two groups, one managed with the currently recommended 
strategy (medical treatment until symptoms arise or LVEF drops below 50%) and one to be treated with 
elective AVR. The primary outcome of the study is a composite variable of all-cause death, acute 
myocardial infarction, stroke or unplanned hospitalization for heart failure. Secondary outcomes will 
include a safety analysis to determine whether the early surgery group suffers from any increase in 
operative and in hospital mortality, or from an increase in valve related complications, when compared to 
patients operated after symptom onset.63 This trial will definitely contribute to expand the knowledge 
about the best timing for AVR.  
POSSIBLE ROLE OF LVR AND LVH FROM A THERAPEUTIC AND 
PROGNOSTIC STANDPOINT 
This review of current information, summarized in Table 3, regarding LVH in the context of AS revealed 
a large amount of relevant information that can potentially be utilized to support the inclusion of LVH in 
operative criterion for AS. 
Regarding echocardiography, data exists supporting an expansion of the hemodynamic characteristics 
evaluated64, and the usage of Integrated Backscatter (IBS)65 techniques, which are a form of 
echocardiographical characterization of myocardial tissues, shows great promise. Cyclic Variation of IBS 
(CVIBS), mean IBS at end diastole (IBSed), and mean Cyclic Variation of IBS index (CVIBSi) have 
value as predictors of LVRR in a post-AVR setting: CVIBS showed a sensitivity of 84.6% and specificity 
of 63.1%. using values equal to or greater than 5.1 dB as a cut- off. IBSed showed a sensitivity of 84.6% 
and specificity of 78.9% using values equal to or greater than 34 dB as a cut-off. CVIBSi showed a 
sensitivity of 79.5% and specificity of 84.2% using values equal to or greater than 15.7% as a cut-off66. 
Echocardiographic strain measurements have also shown potential. Two-dimensional back longitudinal 
scatter shows a strong association with adverse outcomes for the asymptomatic AS patient, when values 
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lower than 13% are found,67 and 3 dimensional global longitudinal strain has a sensitivity and specificity 
of 76% and 77%, for a cutoff value of -14.5 for predicting MACE, also in asymptomatic AS patients. 
The usage of MRI also shows potential for expansion. LGE; as said above, is the quintessential method 
for evaluating the midwall myocardial fibrosis occurring in LVH. LGE and LVMi share an independent 
association with plasma cTnI concentrations68, and LGE is also independently associated with the 
aforementioned echocardiographic strain measurements69. Midwall fibrosis as measured by LGE in an 
MRI appears associated with an 8 fold increased risk of all-cause mortality in moderate to severe AS 
patients38.  
The common electrocardiogram also shows interest, as measurements of LVH and LV strain have a 
direct, independent relationship with prognosis70. 
Perhaps the most interesting data comes in the domain of biomarkers. The usage of high sensitivity 
cardiac Troponin T (hs-cTnT) assays is particularly relevant, as high circulating titers of hs-CTnT are 
associated with poor prognosis even in asymptomatic AS patients71, namely cardiovascular death or need 
for future AVR68. B-type Natriuretic Peptide (BNP) is also relevant. Lower levels of NT-BNP correlate 
with higher magnitudes of LMVi normalization and better quality of life in a post-AVR setting72. In a 
groundbreaking study, Gárcia et al73 demonstrated the potential relevance of titers of miR-133a in the 
timing of the surgical decision for AVR, as higher titers of pre-operative circulating miR-133a revealed 
greater potential for LVMi normalization post-op. 
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DISCUSSION 
LIMITATIONS OF CURRENT GUIDELINES  
As of today, the usage of LVH and markers thereof is sparse for therapeutic decision in the context of AS. 
While the 2012 ES/EACTS1 guidelines already include LVH when recommending AVR for 
asymptomatic patients, with normal exercise testing, low surgical risk and an excess of LVH in the 
absence of hypertension, the class of recommendation is only IIB, and the contemporary 2014 AHA 
guidelines17 make no reference whatsoever to these potentially useful markers. 
The current management strategy recommended by both European and American guidelines is also a 
subject of controversy, with large, multi-center studies showing the currently recommended strategy of 
“watchful waiting” prompts a dismal outcome. 
With this in mind, several studies have attempted to uncover other parameter that might help to clarify the 
best time for ABR. For instance, in 2012, Carabello recommended AVR for asymptomatic AS patients 
with either a positive exercise test; heavy valve calcification; documented rapid progression of AS from 
serial measurements; excessive left ventricular hypertrophy; or rising natriuretic peptides,74 differing from 
the established guidelines. 
Various studies found that the persistence of LVH in a post AVR or TAVI setting is associated with 
worse outcomes, like an increase in risk of MACE, all-cause death, or cardiac re-hospitalization. There 
appears to be a trend showing that while men more frequently exhibit maladaptive cardiac remodeling 
when compared to women, women have a worse prognosis in comparison to men when said remodeling 
is present54. 
All of these potentially useful markers of prognosis can be evaluated using studies which are already 
performed on a routine basis for AS patients (echocardiography, electrocardiography, blood 
measurements and MRI), and thus there would be virtually no impediment to the incorporations of these 
new measures in newer editions of the guidelines should their utility be confirmed.  
However, to fully recommend a change in guidelines, more research is needed. It would be essential to 
determine whether earlier surgery is associated with better LVH regression and better prognosis. With 
this objective in mind, the AVATAR study63 begun in 2016, will provide key information. 
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Either way, data shows that the risk-benefit analysis regarding surgical recommendation in asymptomatic 
AS is overly simplistic, overlooking various highly useful markers of prognosis. The construction on an 
integrated risk score for these patients, utilizing various prognostic markers apart from hemodynamic 
measurements, like echocardiographic LV strain and LVH, electrocardiographic LVH and LV strain, 
various biomarkers and MRI markers, could be integrated into future guidelines to recommend earlier 
surgery for asymptomatic AS patients with a particularly dire prognosis.  
CONCLUSIONS 
While further studies are essential to cement these conclusions, the weight of recent data appears to 
indicate that current guidelines present an overly simplistic risk-benefit analysis regarding the surgical 
decision for AS patients, and an overly passive and conservative approach to asymptomatic AS patients. 
The association of LVH, its echocardiographic translation, namely ECG strain, and various cardiac 
biomarkers, with the occurrence of MACE and prognosis even in asymptomatic patients herald great 
potential in the design of a newer, more complete integrated risk score for AS, which could reveal 
asymptomatic patients with an exceptionally dire prognosis and this, with great potential benefit from 
more proactive surgical interventions, as is illustrated in Figure 2. 
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ANNEX: FIGURES 
 
Figure 1 - Review flowchart 
 
Figure 2 - The usage of markers of LVH could bring a paradigm shift in the surgical timing of AS. 
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ANNEX: TABLES 
Stage Definition 
A At Risk of AS 
B Progressive AS 
C Asymptomatic Severe AS 
C1 Asymptomatic Severe AS 
C2 Asymptomatic Severe AS with LV Dysfunction 
D Symptomatic Severe AS 
D1 Symptomatic Severe High-Gradient AS 
D2 Symptomatic Severe Low-Flow\Low-Gradient AS 
with Reduced LVEF 
D3 Symptomatic Severe Low-Gradient AS with 
normal LVEF or Paradoxical Low-Flow Severe 
AS 
Table 1 - Summary of AS Stages. Adapted from AHA Guidelines for the Management of Patients with Valvular Disease.17 
Recommendations COR LOE 
AVR is indicated in patients with severe AS and any symptoms related to AS. I B 
AVR is indicated in patients with severe AS undergoing Coronary Artery 
Bypass Graft, surgery of the ascending aorta or another valve. 
I C 
AVR is indicated in asymptomatic patients with severe AS and systolic LV 
dysfunction (LVEF <50%) not due to another cause. 
I C 
AVR is indicated in asymptomatic patients with severe AS and abnormal 
exercise test showing symptoms on exercise clearly related to AS. 
I C 
AVR should be considered in high risk patients with severe symptomatic AS 
who are suitable for TAVI, but in whom surgery is favoured by a ‘heart team’ 
based on the individual risk profile and anatomic suitability 
IIa B 
AVR should be considered in asymptomatic patients with severe AS and 
abnormal exercise test showing fall in blood pressure below baseline 
IIa C 
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AVR should be considered in patients with moderate AS undergoing Coronary 
Artery Bypass Graft, surgery of the ascending aorta or another valve. 
IIa C 
AVR should be considered in symptomatic patients with low flow, low gradient 
(<40 mmHg) AS with normal EF only after careful confirmation of severe 
AS.e 
AVR 
IIa C 
AVR should be considered in symptomatic patients with severe AS, low flow, 
low gradient with reduced EF, and evidence of flow reserve 
IIa C 
AVR should be considered in asymptomatic patients, with normal EF and none 
of the above mentioned exercise test abnormalities, if the surgical risk is low, 
and one or more of the following findings is present: Very severe AS defined 
by a peak transvalvular velocity >5.5 m/s; Severe valve calcification and a rate 
of peak transvalvular velocity progression ≥0.3 m/s per year. 
IIb C 
AVR may be considered in symptomatic patients with severe AS low flow, low 
gradient, and LV dysfunction without flow reserve. 
IIB C 
AVR may be considered in asymptomatic patients with severe AS, normal EF 
and none of the above mentioned exercise test abnormalities, if surgical risk is 
low, and one or more of the following findings is present: Markedly elevated 
natriuretic peptide levels confirmed by repeated measurements and without 
other explanations; Increase of mean pressure gradient with exercise by >20 
mmHg; Excessive LV hypertrophy in the absence of hypertension. 
IIB C 
Table 2 - Summary of Recommendations in AS: Timing of Intervention. COR, class of recommendation; LOE, level of evidence. 
Adapted from the ESC/EACTS Guidelines on the Management of Valvular Heart Disease 1 
Authors Date Aims Population and Methods Relevant Findings 
Gavina et al54 2016 Evaluate whether 
residual LV hypertrophy 
is associated with clinical 
outcomes after AVR in 
severe AS. 
In a prospective cohort of 
132 patients with severe 
AS with a mean follow-
up was 6.0 ± 1.5 years, 
clinical and 
Residual LVH was 
present in 44% of patients 
after AVR. The risk of 
all-cause death and non-
fatal cardiovascular 
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echocardiographic 
parameters were 
evaluated in a pre-op and 
post-op setting. Clinical 
endpoints were all-cause 
death and combination of 
in all-cause death and 
non-fatal cardiovascular 
hospitalization. 56 
random patients  went 
biopsies during AVR for 
collagen volume fraction 
evaluation.   
hospitalization was 
higher in patients with 
residual LVH. Residual 
LVH was associated with 
a worse outcome in 
women but not in men. 
Debry et al75 2016 Evaluate the prognostic 
significance of LV 
concentric remodeling 
(LVCR) in the context of 
AS. 
331 patients with AS and 
an LVEF > 50% were 
enrolled. The endpoints 
were mortality with 
conservative management 
and mortality with 
conservative and/or 
surgical management. 
Among the patterns of LV 
geometry in AS, LVCR 
portends the worst 
outcome. Patients with 
LVCR and AS have a 
considerable increased 
risk of mortality, 
regardless of clinical 
management. 
Güçlü et al76 2015 Investigate whether 
myocardial efficiency is 
reduced in patients with 
LVH caused by AS and 
to assess the effect of 
AVR on myocardial 
efficiency in relation to 
exercise capacity. 
Echocardiography, 
cardiopulmonaryexercise 
test, positron emission 
tomography and 
cardiovascular MRI were 
performed in 10 AS 
patients before AVR and 
4 months after AVR. 
Myocardial external 
efficiency is significantly 
reduced in patients with 
AS-induced LVH, and it’s 
improvement is an 
important predictor of 
AVR-induced 
improvement of exercise 
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Fourteen healthy 
individuals served as 
control group. 
capacity in AS patients. 
Sjöberg et al77 2015 Evaluate 
electrocardiographic 
LVH criteria as a method 
of diagnosing and 
quantifying LVH in 
patients with AS 
undergoing TAVR. 
24 patients underwent 
pre-TAVR 
electrocardiography and 
echocardiograph. The 
electrocardiographs were 
evaluated using the 
Sokolow–Lyon, 
Romhilt–Estes and 
Cornell Voltage criteria 
for LVH as well as 
spatial maximal QRS-T 
angle and 3D QRS 
maximal spatial vector. 
The LVM was measured 
by echocardiography. 
There was no correlation 
between LVM and 
conventional 
electrocardiographic LVH 
criteria or spatial 
parameters.  
In TAVR patients, none of 
the ECG LVH criteria 
should be used for 
evaluation of LVM. 
Carstensen et 
al67 
2015 Compare velocity, via 
color Doppler tissue 
imaging and deformation 
via two-dimensional 
speckle-tracking 
echocardiography, in 
relation to global and 
regional longitudinal 
function in asymptomatic 
and severe symptomatic 
AS. 
231 patients with aortic 
stenosis were divided into 
four groups: asymp- 
tomatic moderate AS; 
asymptomatic severe AS; 
and symptomatic severe 
aortic stenosis with 
preserved; and reduced 
LVEF. 
Only diastolic e0, 
longitudinal 
displacement, and basal 
longitudinal strain (BLS) 
remained significantly 
associated with 
symptomatic status, 
independent of other 
factors. 
BLS has the strongest 
association with 
symptomatic status, and 
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BLS <13% is related to 
adverse outcomes in 
severe asymptomatic AS. 
Helske-Suihko 
et al78 
2015 Ascertain whether 
candesartan, favorably 
influences LV structure 
and function and 
improves exercise 
capacity in AS patients. 
51 patients with severe 
AS were randomized to 
receive candesartan or 
placebo. 8 patients 
discontinued treatment 
.43 patients underwent 
echocardiography, 
walking test, and 
measurement of Nt-
proBNP before and after 
an average of 5-month 
treatment. 
Candesartan was well 
tolerated but had no 
favorable effects on the 
anatomy of the LV or 
effort tolerance. 
Tan et al64 2015 Evaluate the incremental 
predictive value of a 
complete 
echocardiogram in 
identifying high-risk 
surgical candidates in a 
pre-op setting. 
 432 patients with a mean 
age of 73.5 years and 
38.7% females were 
subjected to a full 
preoperative 
echocardiographic study, 
which was evaluated to 
quantify chamber size 
and function and valve 
function. 
Cox regression revealed 5 
echocardiographic 
predictors of all-cause 
mortality: small LV end-
diastolic cavity size; LV 
mass index; mitral 
regurgitation grade; 
right atrial area index; 
and mean aortic 
gradient <40 mm Hg. 
Gerdts et al79 2015 Assess the impact of 
echocardiographic LV 
mass on the rate of major 
cardiovascular events in 
asymptomatic AS 
1656 patients (mean age, 
67 years; 39.6% women) 
with mild-to-moderate 
asymptomatic aortic 
stenosis participating in 
Higher baseline LVMi 
independently  
predicted increases of 
12% for major 
cardiovascular events, 
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patients.  the Simvastatin 
Ezetimibe in Aortic 
Stenosis (SEAS) study 
were followed during 4.3 
years of randomized 
treatment with combined 
simvastatin 40 mg and 
ezetimibe 10 mg daily or 
placebo. 
28% for ischemic 
cardiovascular events, 
34% for cardiovascular 
mortality, and 23% for 
combined total mortality 
and hospitalization for 
heart failure (all P<0.01). 
Higher LVMi is 
independently associated 
with increased 
cardiovascular morbidity 
and mortality during 
progression of aortic 
stenosis. 
Magalhães et 
al55 
2015 Describe the remodeling 
process in patients with 
severe AS who 
underwent TAVI. 
Echocardiographic data 
was collected at baseline, 
30 days, 6 months, and 1 
year, from a cohort of 
333 patients who 
underwent TAVI. 
Patients were categorized 
according to LVMi and 
RWT to one of the four 
common typologies of 
LVH.  Reverse 
remodeling defined as 
normalization of LVMi 
and/or RWT and adverse 
remodeling as an increase 
in LVMi and/or RWT. 
Reverse LV remodeling 
was observed in 24% of 
patients. TAVI reverses 
ventricular remodeling 
and LV hypertrophy 
induced by AS, although 
incompletely, and this 
reversal is not followed by 
a change in left atrial 
dimensions. The clinical 
impact of these findings is 
unclear. 
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Nagata et al80 2015 Determine which 
echocardiographic  LV 
strain component was the 
most powerful predictor 
of major adverse 
cardiovascular events in 
severe asymptomatic AS 
patients. 
104 patients with severe 
asymptomatic AS were 
followed for a median 
follow-up of 374 days, 
and studied with 2-
dimensional speckle 
tracking 
echocardiography and 3-
dimensional speckle-
tracking 
echocardiography and 
recording any major 
adverse cardiovascular 
events.  
3-dimensional global 
longitudinal strain is the 
strongest index for 
predicting future major 
adverse cardiovascular 
events, with a sensitivity 
and specificity of 76% and 
77%, for a cutoff value of 
-14,5%. In a univariate 
analysis, the LVMi also 
had a statistically 
significant association 
with said events. 
Petrov et al81 2014 Study the prognostic 
impact of maladaptive 
remodeling in a post-
AVR setting. 
128 patients who 
underwent AVR for AS 
were 
echocardiographically 
studied at the moment of 
surgery and 4 years later 
Men more often exhibited 
maladaptive LVH, with 
increased fibrosis and 
levels of cardiac fibriosis 
biomarkers.  
The presence of 
maladaptive LVH in 
women was associated 
with worse survival. 
Beach et al82 2014 Understand the factors 
modulating LVRR after 
AVR, the relationship 
between the preoperative 
symptoms and 
modulators of left heart 
remodeling, and their 
Over 17 years, 4264 
patients underwent 
primary aortic valve 
replacement for aortic 
stenosis. Changes in the 
time course of LV 
reverse remodeling were 
LVH rapidly declined 
after surgery, and 
remained relatively 
constant but greater than 
the upper limit of normal. 
The most important risk 
factor for residual LVH 
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influence on long-term 
survival. 
assessed using 5740 post-
op TTE from 3841 
patients. 
was greater preoperative 
LVH. Other factors 
included a greater left 
atrial diameter, a lower 
ejection fraction, and 
male gender. 
Preoperative severe 
LVH and left atrial 
dilatation reduced long-
term survival, independent 
of symptom status. 
Severe LVH with left 
atrial dilatation can 
develop from severe AS, 
even without symptoms. 
These changes can persist 
after AVR, and are 
associated with decreased 
long-term survival. 
Haverich et 
al56 
2014 Analyze the 
intermediate-term 
follow-up data from a 
large series of patients 
enrolled in the Surgical 
Treatment of Aortic 
Stenosis With a Next 
Generation Surgical 
Aortic Valve trial. 
287 patients with AS 
underwent rapid 
deployment aortic valve 
replacement using a 
stented trileaflet bovine 
pericardial bio-prosthesis. 
Core laboratory 
echocardiography was 
performed at baseline, 
discharge, and 3 months, 
1 year, and 3 years post-
At 1 year, LVMi had 
decreased by 14% and at 3 
years by 16% compared 
with the discharge.  
Future studies will 
establish whether these 
favorable structural 
changes correlate with 
improvement in long-term 
survival and functional 
status 
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op. 
Chin et al68 2014 Assess prognostic value 
of high sensitivity 
troponin I concentrations 
in AS as a marker of 
advanced LVH and 
predictor of adverse 
prognosis 
122 patients with AS 
underwent ECG, 
echocardiography, and 
MRI, assessing LV mass, 
function and fibrosis. 
131 patients were 
followed for a median of 
10,6 years to assess the 
outcomes. 
The LVMi and late 
gadolinium enhancement 
were independently 
associated with cTnI 
concentrations. 
Plasma cTnI 
concentrations were 
associated with a hazard 
ratio of 1.77 for 
cardiovascular death or 
AVR, independent of age, 
sex, systolic ejection 
fraction, and aortic 
stenosis severity 
Gavina et al32 2014 Evaluate the impact of 
hypertension on the left 
ventricular mass 
regression in AS after 
AVR. 
135 patients with severe 
aortic stenosis were 
studied at baseline and 1 
year post-op. In 32 
patients we analyzed 
myocardial gene 
expression of collagen 
types I and III, 
connective tissue growth 
factor, transforming 
growth factor-β1, 
metalloproteinase-2 and 
its tissue inhibitor and 
compared its levels vs 
controls. 
Mass regression was 
significantly higher in 
patients without 
hypertension, with a 
median decrease of 25.9%  
vs 5.4%. AS patients had 
increased expression of 
collagen types I and III. 
Hypertensive patients had 
higher relative expression 
of collagen type I vs III 
and TIMP2 expression 
was up-regulated and 
correlated with higher 
baseline LVMi. 
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Lindman et 
al72 
2014 Examine the relationship 
between left ventricular 
mass regression and 
clinical outcomes after 
TAVR. 
 
2115 patients with 
symptomatic AS at high 
surgical risk receiving 
TAVR in the PARTNER 
randomized trial or 
continued access registry. 
Clinical outcomes were 
compared for patients 
with greater than vs. 
lesser than median 
percent change in LVMi . 
Greater LVMi 
regression was associated 
with similar rates of all-
cause mortality, but 
significantly lower rates 
of rehospitalization (for 
all causes, 9.5% vs. 
18.5%; and specifically 
for heart failure 7.3% vs. 
13.6%) lower levels of 
BNP and a trend towards 
better QoL, when 
compared to those with 
lesser regression. 
Shah et al69 2014 Investigate the 
mechanisms and 
outcomes associated with 
LV ECG strain in a 
context of AS. 
To investigate 
mechanism, 102 patients 
were studied via 
electrocardiography, 
echocardiography, and 
cardiovascular MRI. T1 
mapping was used to 
determine diffuse fibrosis 
and late gadolinium 
enhancement to 
determine replacement 
fibrosis. 
To investigate outcomes, 
140 patients were 
followed for a median of 
10,6 years. 
LGE of the midwall was 
present in all patients with 
ECG strain, with positive 
and negative predictive 
values of 100% and 86%, 
respectively, leading to the 
conclusion that ECG 
strain is a specific 
marker of cardiac 
midwall fibrosis. 
Patients with ECG strain 
had greater increases of 
LVMi, higher high-
sensitivity plasma 
cardiac troponin-I 
concentrations, more 
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severe AS, and an 
increase in diffuse 
myocardial fibrosis, 
when compared to those 
without ECG strain. ECG 
strain was found to be an 
independent predictor of 
cardiovascular mortality 
or need for later AVR. 
Ben-Dor et al83 2013 Assess the relationship of 
BNP with AS severity 
and prognosis. 
289 high-risk patients 
with severe AS who were 
referred for TAVI. 
Patients were divided into 
tertiles based on BNP 
level (I, II, III), were 
followed for a median of 
319 days, range 110 to 
655. 
The degree of AS did not 
differ among the 3 groups. 
Mortality rates during a 
median were significantly 
lower in Group I 
compared with Groups II 
and III. However, BNP 
levels did not have an 
independent association 
with mortality when 
adjusted for co-variables. 
At 1-year follow- up post 
TAVI, the mean BNP 
level decreased 
significantly. 
Mannacio et 
al84 
2013 Evaluates BNP as a 
marker of LV diastolic 
dysfunction and the 
relationship between 
BNP values and the 
grade of LV diastolic 
113 AS patients with 
preserved LVEF who 
underwent AVR were 
evaluated preoperatively, 
5 days post-operatively 
and at 12-month follow-
BNP values correlated 
with the degree of 
diastolic dysfunction. 
BNP level of 120 pg/ml 
were 91% sensitive and 
85% specific for diastolic 
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dysfunction. up, via echocardiography, 
to assess LV dimensional 
and functional 
parameters, with 
concomitant 
measurements of BNP. 
disease, while 300 pg/ml 
was 80% sensitive and 
91% specific for moderate 
or severe diastolic 
dysfunction.  
12 months after AVR, 
BNP values were strongly 
correlated with the 
significant 
echocardiographic 
parameters suggestive of 
diastolic dysfunction. 
La Manna et 
al85 
2013 Investigate the degree of 
reverse remodeling of the 
LV and changes in 
function thereof six 
months after TAVI via 
cardiac MRI. 
27 patients, with a mean 
age of 80.7±5.2 years, 
had paired cardiac MRI 
at baseline and at 6-
months post-op, 
measuring LVMi, end 
diastolic volume indexed 
to body surface area 
LVEF and stroke volume. 
Cardiac MRI demonstrates 
significant regression of 
LVH at 6-months post 
TAVI. 
Garcìa et al73 2013 Asses the significance of 
plasma myocardial micro 
RNA 133a, as a 
biomarker capable of 
predicting LVH 
reversibility in post-AVR 
patients 
74 aortic stenosis 
patients. miR-133a 
expression evaluated in 
LV biopsy. Circulating 
miR-133a measured in 
peripheral and coronary 
sinus blood. LV mass 
reduction determined 
echocardiographically 
Levels of miR-133a in the 
myocardium and in the 
plasma were directly 
correlated. Preoperative 
titers of miR-133a were 
higher in those whose LV 
mass normalized after 1 
year. 
miR-133a has great 
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potential for the decision 
of surgical timing, 
particularly for 
asymptomatic patients. 
Eleid et al86 2013 Study the relevance of 
flow gradient patterns in 
Severe AS with 
preserved LVEF. 
1704 consecutive patients 
with severe AS 
and preserved 
ejection fraction using 2-
dimensional and Doppler 
echocardiography 
Low flow\low gradient AS 
has a poorer prognosis 
compared to other variants 
of AS, particularly with a 
higher incidence of atrial 
fibrillation and heart 
failure and with higher 
rates of mortality. In low-
flow\low-gradient AS, 
smaller LVMi (99±30 vs 
112±27 , p<0.05) and 
smaller RWT (0.49±0.08 
vs 0.53±0.09, p>0,05) was 
observed in comparison to 
the classical variant of 
low-flow\high-gradient 
AS.  
Breitenbach et 
al21 
2012 Compare the decrease 
LVMi by MRI vs. 
transthoracic 
echocardiography after 
AVR for severe AS. 
149 patients who 
underwent AVR. 
Transthoracic 
echocardiographic and 
cardiac MRI 
measurements of LVMi 
were made at baseline 
and at 6 months of 
follow-up and were 
Because of the 
overestimation of the 
decrease in LVMi by the 
Devereux formula, as well 
as the higher accuracy and 
reproducibility of cardiac 
MRI measurements, the 
latter should be preferred 
to TTE. 
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compared. Changes in 
mean pressure gradients 
were examined using 
transthoracic 
echocardiography. 
Flett et al87 2012 Determine the clinical 
significance of diffuse 
myocardial fibrosis in 
severe AS before and 
after AVR.. 
Severe AS patients 
underwent 
echocardiography, BNP, 
6 min walk test, and 
and results 
equilibrium contrast 
cardiovascular magnetic 
resonance (EQ-CMR)pre-
op, at baseline and at 6 
months post-op. EQ-
CMR was also performed 
in 30 normal controls 
Diffuse myocardial 
fibrosis is elevated in 
severe AS. It correlates 
with functional capacity at 
baseline. LV 
hypertrophy regression 6 
months after AVR occurs 
via predominantly cellular 
mechanisms.  
Greve et al70 2012 Assess the prognostic 
value of left ventricular 
strain determined via 
electrocardiography, and 
LVH, assessed by 
Sokolow-Lyon voltage 
criteria and Cornell 
voltage-duration criteria, 
in the context of 
asymptomatic AS. 
1533 patients 
participating in the SEAS 
study were followed for  
a median of 4.3 years. 
Primary end points were: 
first episode of 
myocardial infarction, 
nonhemorrhagic stroke, 
heart failure, aortic valve 
replacement, or 
cardiovascular death. 
ECG left ventricular 
strain was associated with 
a 3,1 times greater risk of 
myocardial infarction, and 
that ECG LVH 
determined by both 
criteria was associated 
with a 2,5 times greater 
risk of either myocardial 
infarction, heart failure, or 
cardiovascular death. 
Vizzardi et al88 2012 Investigate the effects of 
TAVI LVH and diastolic 
135 patients who 
underwent TAVI had an 
Significant LVRR 
measure by reductions in 
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function in patients with 
severe AS. 
echocardiographic and 
clinical assessment 
performed at baseline and 
at 6 months. 
LV mass and LVMi, 
associated with 
improvement in LV 
systolic and diastolic 
function was found in 
patients with severe AS 6 
months post-op. 
Røsjø et al71  2011 Study the prognostic 
value and relation to 
echocardiographic 
indexes of cardiac 
function and anatomy of 
circulating hs-cTnT in 
AS.  
57 AS patients with 
myocardial hypertrophy 
underwent 
echocardiographic study. 
hs-cTnT levels were 
linked to prognosis and 
echocardiographic 
indexes of myocardial 
structure and function 
In moderate and severe 
AS patients, TnT levels 
are universally detectable 
using high sensitivity 
assays, LV mass and 
systolic function, are 
determinants of hs-cTnT 
levels; and high hs-cTnT 
levels are associated with 
a poor prognosis.  
Dweck et al38 2011 Assess the prognostic 
significance of midwall 
and infarct patterns of 
late gadolinium 
enhancement in AS. 
A total of 143 patients 
who underwent 
gadolinium contrast MRI 
were categorized into 
absent, midwall, or 
infarct patterns of LGE 
and were followed for 2 
years. 
Midwall fibrosis was 
associated with 8 times 
greater, and the infarct 
pattern with 6-times 
greater all-cause mortality, 
despite similar aortic 
stenosis severity and 
coronary artery disease 
burden. 
Midwall fibrosis and 
ejection fraction were 
independent predictors of 
all-cause mortality. 
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Cioff et al89 2011 Determine the prognostic 
impact of LVH in the 
context of asymptomatic 
severe AS. 
209 patients had a 
complete clinical and 
imagiologic data after a 
median follow-up of 22 
months.  
LVH is common in 
patients with 
asymptomatic severe AS 
and is associated with an 
increased rate of 
cardiovascular events 
independent of other 
prognostic covariates. 
Dahl et al90 2011 Study the relation of left 
atrial pressure overload 
in severe AS to 
ventricular remodeling 
and clinical outcome 
after AVR. 
119 patients with severe 
AS scheduled for AVR 
were evaluated. 
Echocardiography was 
repeated 12 months after 
surgery. Patients were 
followed up for 24 
months. 
Preoperative left atrial 
dilation was associated 
with LVH and increased 
filling pressure. 
Preoperative left atrial 
volume index was 
associated with persistent 
abnormalities in left 
ventricular filling pressure 
and LVMi at 1 year after 
surgery.  
In patients with 
symptomatic severe AS 
undergoing AVR, left 
atrial volume provides 
important prognostic 
information beyond 
standard risk factors 
Fijalkowski et 
al66 
2010 Evaluate possible 
changes between pre- 
and post-op studies of 
echocardiographic 
58 patients with AS. 
Average follow-up of 18 
+- 5 months after AVR. 
Traditional transthoracic 
Significant regression of 
LVH parameters, namely 
RWT, septum thickness 
and LMVi, were observed 
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integrated backscatter 
(IBS) parameters of LV 
systolic and diastolic 
dysfunction and 
determine whether pre-
op IBS parameters were 
capable of predicting 
post-op LV reverse 
remodeling. 
echocardiography and 
analysis of IBS 
reflectivity were 
performed before AVR 
and during the control 
visit after AVR. 
 
post-op, and a ROC 
under-the-curve showed 
that CVIBS , mean 
IBSed, and mean 
CVIBSi have similar 
capacities to predict LV 
reverse remodeling.. 
 
Stewart et al91 2010 Determine if tissue 
Doppler measures of LV 
systolic and/or diastolic 
function or 
echocardiographic LVH 
are useful for stratifying 
asymptomatic patients 
with severe calcific AS 
according to risk. 
183 initially 
asymptomatic patients 
with moderate or severe 
AS and a normal LVEF 
were followed for median 
31 months. Peak systolic 
and diastolic mitral 
annular velocities and LV 
mass were measured by 
echocardiography at 
baseline and during 
follow-up. 
Tissue Doppler measures 
of LV systolic and 
diastolic function and LV 
mass provide limited 
predictive information 
after accounting for the 
severity of stenosis. 
Villar et al92 2009 Determine whether 
plasma TGF-b1 relates 
with myocardial 
remodeling, reflected by 
LV transcriptional 
adaptations of genes 
linked to myocardial 
hypertrophy and fibrosis, 
and by heart morphology 
39 AS patients who 
underwent AVR, 27 
healthy volunteers; 12 
mice subjected to 
transverse aortic arch 
constriction; and 6 mice 
who underwent sham 
surgery. 
A circulating TGF-b1-
mediated mechanism is 
involved, in both mice and 
humans, in the excessive 
deposition of extracellular 
elements and hypertrophic 
growth of cardiomyocytes 
under pressure overload. 
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and function. 
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